Sulofenur | LY186641 | CAS#110311-27-8

MedKoo Cat#: 205995 | Name: Sulofenur

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sulofenur is a diarylsulfonylurea with potential antineoplastic activity. Sulofenur's antineoplastic mechanism of action is unknown.

Chemical Structure

Sulofenur

CAS#10311-27-8

Theoretical Analysis

MedKoo Cat#: 205995

Name: Sulofenur

CAS#: 10311-27-8

Chemical Formula: C16H15ClN2O3S

Exact Mass: 350.0492

Molecular Weight: 350.82

Elemental Analysis: C, 54.78; H, 4.31; Cl, 10.11; N, 7.99; O, 13.68; S, 9.14s

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Sulofenur; LY186641; LY-186641; LY 186641.

IUPAC/Chemical Name

N-((4-chlorophenyl)carbamoyl)-2,3-dihydro-1H-indene-5-sulfonamide

InChi Key

JQJSFAJISYZPER-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H15ClN2O3S/c17-13-5-7-14(8-6-13)18-16(20)19-23(21,22)15-9-4-11-2-1-3-12(11)10-15/h4-10H,1-3H2,(H2,18,19,20)

SMILES Code

O=S(C1=CC2=C(CCC2)C=C1)(NC(NC3=CC=C(Cl)C=C3)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>5 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 350.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Guan X, Hoffman BN, McFarland DC, Gilkerson KK, Dwivedi C, Erickson AK, Bebensee S, Pellegrini J. Glutathione and mercapturic acid conjugates of sulofenur and their activity against a human colon cancer cell line. Drug Metab Dispos. 2002 Mar;30(3):331-5. PubMed PMID: 11854154. 2: Jochheim CM, Davis MR, Baillie KM, Ehlhardt WJ, Baillie TA. Glutathione-dependent metabolism of the antitumor agent sulofenur. Evidence for the formation of p-chlorophenyl isocyanate as a reactive intermediate. Chem Res Toxicol. 2002 Feb;15(2):240-8. PubMed PMID: 11849051. 3: Krarup-Hansen A, Pedersen H, Andersen E, Andersen H, Hansen HH. Early clinical investigation of sulofenur with a daily schedule in advanced solid tumours. Invest New Drugs. 1997;15(2):147-51. PubMed PMID: 9220294. 4: Gu H, Smith MW, Phelps PC, Berezesky IK, Merriman RL, Boder GB, Trump BF. H-ras transfection of the rat kidney cell line NRK-52E results in increased induction of c-fos, c-jun and hsp70 following sulofenur treatment. Cancer Lett. 1996 Sep 10;106(2):199-205. PubMed PMID: 8844973. 5: Phelps PC, Best CJ, Berezesky IK, Merriman RL, Tanzer LR, Boder GB, Trump BF. Studies on the mechanism of sulofenur and LY295501 toxicity: effect on the regulation of cytosolic calcium in relation to cytotoxicity in normal and tumorigenic rat kidney cell lines. Cancer Lett. 1995 Oct 20;97(1):7-15. PubMed PMID: 7585481. 6: Houghton PJ, Cheshire PJ, Myers L, Lutz L, Toth J, Grindey GB, Houghton JA. Efficacy of sulofenur and a second generation diarylsulfonylurea, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea (LY295501), against colon adenocarcinoma xenografts. Anticancer Drugs. 1995 Apr;6(2):317-23. PubMed PMID: 7795279. 7: Houghton PJ, Sosinski J, Thakar JH, Boder GB, Grindey GB. Characterization of the intracellular distribution and binding in human adenocarcinoma cells of N-(4-azidophenylsulfonyl)-N'-(4-chlorophenyl)urea (LY219703), a photoaffinity analogue of the antitumor diarylsulfonylurea sulofenur. Biochem Pharmacol. 1995 Mar 1;49(5):661-8. PubMed PMID: 7887981. 8: Phelps PC, Jain PT, Berezesky IK, Boder GB, Trump BF. Sulofenur cytotoxicity and changes in cytosolic calcium and mitochondrial membrane potential in human colon adenocarcinoma cell lines. Cancer Lett. 1995 Jan 6;88(1):27-35. PubMed PMID: 7850770. 9: Pratt CB, Bowman LC, Marina N, Pappo A, Avery L, Luo X, Meyer WH. A phase I study of sulofenur in refractory pediatric malignant solid tumors. Invest New Drugs. 1995;13(1):63-6. PubMed PMID: 7499110. 10: Brown TD, O'Rourke TJ, Kuhn JG, Craig JB, Havlin K, Burris HA 3rd, Cagnola J, Hamilton JM, Grindey GB, Satterlee WG, et al. Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule. Anticancer Drugs. 1994 Apr;5(2):151-9. PubMed PMID: 8049498.